araag2/HINT huggingface dataset:
Clinical trial NCT01437735 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: qaw039, montelukast, placebo
SMILES: CC1=C(CC(O)=O)C2=CC=CN=C2N1CC1=CC=C(C=C1C(F)(F)F)S(C)(=O)=O, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Physician diagnosis of asthma, as per the Global Initiative for Asthma (GINA) (2009)
             guidelines, and currently prescribed Inhaled Corticosteroids (ICS) therapy.

          -  Patients with a pre-bronchodilator Forced Expiratory Volume in 1 second (FEV1) value
             of 40% to 80% of individual predicted value.

          -  Patients should be allergic or atopic, as diagnosed historically or prior to entry
             into the study.

          -  Patients who are demonstrated to have reversible airway obstruction or airways
             hyper-reactivity or have shown either of such responses in previous test(s) within the
             last year.

          -  An Asthma Control Questionnaire (ACQ) score ≥ 1.5 at randomization.

        Exclusion Criteria:

          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive human chorionic gonadotropin (hCG) laboratory test (> 5 mIU/mL).

          -  Patients with serious co-morbidities including uncontrolled diabetes (HbA1c≥8%), heart
             failure, cancer, neurodegenerative diseases, rheumatoid arthritis and other autoimmune
             diseases, other lung diseases including chronic bronchitis, chronic obstructive
             pulmonary diseases or emphysema or other conditions characterized by eosinophilia and
             pulmonary symptoms (i.e. Churg-Strauss syndrome, allergic bronchopulmonary
             aspergillosis, eosinophilic pneumonia, etc.).

          -  Acute illness other than asthma at the start of the study

          -  History of life-threatening asthma, including a history of significant hypercarbia
             (pCO2>45mmHg), prior intubation, respiratory arrest, or seizures as a result of
             asthma.

          -  Patients who have had a respiratory tract infection within 4 weeks of the screening
             visit. Patients who develop a respiratory tract infection between screening and the
             randomization visit must be screen failed, and may be permitted to re-enroll at a
             later date.

          -  Current smokers or ex-smokers who stopped smoking within 6 months prior to screening
             or have a smoking history of ≥ 10 pack years.
Clinical trial NCT00559962 (phase 2, status: completed)
Conditions: hyperlipidemia
ICD codes: E78.2, E78.49, E78.5
Drugs: aegr-733, placebo, aegr-733, aegr-733, aegr-733, aegr-733 and atorvastatin, aegr-733 and fenofibrate, aegr-733 and ezetimibe
SMILES: FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12, FC(F)(F)CNC(=O)C1(CCCCN2CCC(CC2)NC(=O)C2=C(C=CC=C2)C2=CC=C(C=C2)C(F)(F)F)C2=CC=CC=C2C2=CC=CC=C12, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1, O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          1. LDL-C between 100 and 190 mg/dL

          2. Hepatic fat under 6.2% per MRS

        Exclusion Criteria:

          1. Pregnant or lactating females

          2. Uncontrolled hypertension >180/95 mmHg

          3. Chronic renal insufficiency - serum creatinine >2.5 mg/dL at screen

          4. Liver disease; i.e., hepatitis, cirrhosis

          5. Major surgery within 3 months of screen

          6. Cardiac insufficiency

          7. Hx of malignancy other than basal or squamous cell within past 5 yrs

          8. Participation in any investigational drug study within 6 wks of screen

          9. Prior exposure to AEGR-733 in past 12 months

         10. Serious or unstable medical or psychological conditions

         11. More than one alcoholic drink per day

         12. Regular consumption of grapefruit juice or meds known to be metabolized by CYP 3A4

         13. Currently taking corticosteroids

         14. Other lipid-lowering meds (washout permitted)

         15. Fish oil, niacin grater than 200 mg/day and herbal weight loss products (washout
             permitted)

         16. Acute CVD or event within previous 6 months

         17. Diabetes Mellitus

         18. Hepatitis B or C

         19. Medicated COPD

         20. Idiopathic pulmonary fibrosis

         21. G.I. disorders that cause chronic diarrhea

         22. Fasting triglycerides =/> 400 mg/dL

         23. Body Mass Index > 35kg/m2
Clinical trial NCT00692445 (phase 2, status: completed)
Conditions: major depressive disorder, depression
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40, F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: tc-5214 + citalopram, placebo + citalopram
SMILES: CNC1(C)C2CCC(C2)C1(C)C, CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Diagnosis of major depressive disorder (MDD) according to DSM-IV and confirmed via
             MINI diagnostic scale

          2. No more than 1 prior antidepressant course of treatment before trial entry.

          3. Able to give written informed consent.

          4. MADRS score greater than 27.

          5. CGI-S score greater than or equal to 4.

          6. No clinically significant abnormality on physical examination, vital signs, ECG or
             laboratory tests at screening.

          7. Women of child bearing potential must: a) have a negative urine pregnancy test, b) not
             be nursing, and c) be willing to use acceptable methods of contraception throughout
             the study period.

        Exclusion Criteria:

          1. Any co morbid psychiatric illness confirmed by MINI diagnostic scale, especially
             bipolar disorder, schizophrenia, dementia, or PTSD

          2. Subjects with significant suicidal risk upon clinical assessment utilizing the
             M.I.N.I.

          3. History of alcohol or drug abuse over the last 6 months

          4. History of seizures or seizure disorders

          5. Any other severe progressive and uncontrolled medical condition

          6. For other controlled medical conditions, medication to be unchanged over the 2 months
             preceding screening, or else the subject will be excluded

          7. Subjects with Glaucoma, Kidney Disease or Heart Disease

          8. Known hypersensitivity to mecamylamine

          9. Other investigational drug in previous 30 days

         10. Screening QTcB or QTcF > 450 msec

         11. Current or prior citalopram treatment
Clinical trial NCT00401843 (phase 2, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: bortezomib, placebo, dexamethasone
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Measurable secretory disease defined as either serum monoclonal paraprotein,
             (M-protein) greater than or equal to (>=)1 gram per deciliter (g/dL) or urine
             monoclonal (light chain) protein (> 200 mg/24 hours)

          -  Documented disease progression after at least 1 prior line of therapy but no more than
             3 or have had no response to previous treatment (primary refractory disease)

          -  ECOG performance status score of less than or equal to (<=) 2

          -  Adequate bone marrow, liver, and renal function

        Exclusion Criteria:

          -  No prior treatment with bortezomib

          -  Not Refractory to high-dose dexamethasone

          -  Not >= Grade 2 peripheral neuropathy

          -  Have not received an allogeneic bone marrow or allogeneic peripheral blood stem cell
             transplant

          -  No prior or concomitant malignancy (other than multiple myeloma) except adequately
             treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the
             cervix, or other cancer for which the patient has been disease-free for <= 3 years
Clinical trial NCT01259284 (phase 2/phase 3, status: terminated)
Conditions: advanced cancers
ICD codes: K74.02, G47.22, H35.3133, H35.3134, H35.3113, H35.3114, H35.3123
Drugs: atorvastatin
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Reason stopped: 
    terminated due to low accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Patients need to be in a normal sinus rhythm preoperatively.

          2. Participants undergoing planned lobectomy and 60 years of age or older or participants
             undergoing planned pneumonectomy and 18 years of age or older.

          3. Planned procedure is 5 days after the start of taking study drugs.

          4. Signed written informed consent

          5. Women of childbearing potential must have a negative pregnancy test (A woman of
             childbearing potential is a women who has not been naturally postmenopausal for at
             least 12 consecutive months or who has not undergone previous surgical sterilization)

          6. Adequate liver function evidenced by; aspartate aminotransferase (AST or SGOT) </= 2.5
             * Upper Limits of Normal (ULN), and alanine aminotransferase (ALT or SGPT) </= 2.5 *
             ULN

        Exclusion Criteria:

          1. Any history of supraventricular arrhythmia for which the patient is taking
             medications.

          2. Current use of antiarrhythmic medications other than beta-receptor antagonists,
             calcium-channel antagonists, or digitalis.

          3. Use of any supplemental n-3 fatty acids during the previous three months.

          4. Use of any statin therapy during the previous three months.

          5. Patients known to have a history of recent drug or alcohol abuse.

          6. Known allergy to seafood

          7. Current use of Gemfibrozil and Fenofibrate.
Clinical trial NCT00032643 (phase 2, status: terminated)
Conditions: congestive heart failure
ICD codes: I50.20, I50.21, I50.22, I50.30, I50.31, I50.32, I50.40
Drugs: ditpa
SMILES: OC(=O)CCC1=CC(I)=C(OC2=CC=C(O)C=C2)C(I)=C1
Reason stopped: 
    funding support withdrawn (much slower than expected enrollment)
  
Eligibility criteria:

        Inclusion Criteria:

        INCLUSION

        To be enrolled, patients must:

          1. be veterans,

          2. have moderately severe CHF (NYHA class II, III or IV),

          3. be 18 or older,

          4. not have clinically important renal, hepatic or hematological disorders or clinically
             significant abnormal laboratory findings,

          5. not have a pre-existing thyroid disease,

          6. not have anemia (hematocrit less than 30%),

          7. not have chronic pulmonary disease that limits exercise tolerance or requires use of
             chronic bronchodilator therapy or steroids,

          8. be able to walk on the level for 6 minutes,

          9. not have hemodynamically significant pericardial disease,

         10. not have angina pectoris severe enough to require frequent administration of
             sublingual nitroglycerin,

         11. not have acute myocardial infarction within 6 months of screening,

         12. not have inoperable aortic stenosis,

         13. not have symptomatic ventricular arrhythmias or ventricular arrhythmia requiring
             pharmacological therapy,

         14. not have implanted cardioverter defibrillator,

         15. not be taking amiodarone,

         16. not have demonstrated non-compliance with prior medical regimes;

         17. not be on an investigational drug,

         18. not have a medical condition that, in the investigator's opinion, would make the
             patient ineligible,

         19. not have an allergy to iodine or shellfish,

         20. not be in sinus rhythm,

         21. not be of childbearing potential,

         22. have an ejection fraction greater than 40%.

        Exclusion Criteria:
Clinical trial NCT01093807 (phase 2, status: completed)
Conditions: essential hypertension
ICD codes: I10, O10.02, O10.03, O10.011, O10.012, O10.013, O10.019
Drugs: placebo, lercanidipine, lercanidipine, enalapril, enalapril, lercanidipine + enalapril, lercanidipine + enalapril, lercanidipine + enalapril, lercanidipine + enalapril
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1, COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1, CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O, CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O, COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1, COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1, COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1, COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Office Blood Pressure (BP): Sitting diastolic blood pressure (SDBP)100-109 mmHg
             (inclusive) and sitting systolic blood pressure (SSBP) < 180 mmHg after a 2 week
             placebo run-in period

          -  Home Blood Pressure: diastolic blood pressure (DBP)at home ≥ 85 mmHg in the last week
             of the placebo run-in period

          -  Normal Electrocardiogram (ECG), first degree Atrioventricular block or other changes
             not considered clinically significant

        Exclusion Criteria:

          -  Secondary or severe hypertension

          -  History of cerebro- or cardiovascular complications

          -  Type 1 or Type 2 diabetes on drug treatment

          -  Severe renal or hepatic insufficiency
Clinical trial NCT01282476 (phase 2, status: terminated)
Conditions: diffuse large b cell lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: panobinostat with rituximab
SMILES: [H]\C(=C(\[H])C1=CC=C(CNCCC2=C(C)NC3=CC=CC=C23)C=C1)C(O)=NO
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Relapsed or refractory DLBCL

          -  More than 1 line of prior chemotherapy

        Exclusion Criteria:

          -  Currently receiving anticancer therapy or investigational agents

          -  Major surgery within last 4 weeks

          -  Known leptomeningeal or brain metastases

          -  Known HIV infection

          -  Uncontrolled fungal, bacterial, viral or other infection

          -  History of another malignancy (except for non-melanoma skin cancer or in situ cervical
             or breast cancer) unless disease free for at least 3 years

          -  Hepatitis B or C positive

          -  GI disease

          -  Pregnant or breastfeeding

          -  Prior treatment with an HDAC inhibitor including valproic acid
Clinical trial NCT00517868 (phase 2, status: completed)
Conditions: painful bladder syndrome, interstitial cystitis
ICD codes: D68.61, D69.41, D81.4, E24.1, E26.01, E26.81, E34.0, N30.10, N30.11
Drugs: urg101, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  male and female subjects >= 18 years of age

          -  moderate to severe symptoms of PBS/IC

          -  minimum pain/urgency/frequency scores

          -  female subjects on hormone therapy must be on stable dose for >= 3 months

        Exclusion Criteria:

          -  positive pregnancy test or pregnant or lactating

          -  narcotics or medical marijuana within 3 months

          -  use of any investigational drug or device within 30 days

          -  bacterial cystitis within 30 days
Clinical trial NCT00085371 (phase 2, status: completed)
Conditions: acinar cell adenocarcinoma of the pancreas, duct cell adenocarcinoma of the pancreas, recurrent pancreatic cancer, stage iii pancreatic cancer, stage iv pancreatic cancer
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8, C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8, C25.3, C25.3, C25.3
Drugs: triapine
SMILES: NC(=S)N\N=C\C1=C(N)C=CC=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas

               -  Unresectable disease

               -  Locally advanced or metastatic disease

          -  At least 1 unidimensionally measurable lesion >= 20 mm by conventional techniques OR
             >= 10 mm by spiral CT scan

               -  Measurable lesions outside prior radiotherapy field OR measurable lesions
                  actively growing in the site of prior radiotherapy

          -  No prior chemotherapy OR previously treated with 1, and only 1, gemcitabine-containing
             regimen for metastatic, unresectable, or locally advanced pancreatic cancer

               -  Adjuvant therapy not considered prior chemotherapy if all treatment was completed
                  > 6 months before tumor recurrence

          -  No known brain metastases

          -  Performance status - ECOG 0-2

          -  At least 6 weeks

          -  Absolute neutrophil count >= 1,500/mm^3

          -  Platelet count >= 75,000/mm^3

          -  AST =< 3 times upper limit of normal (ULN)

          -  Bilirubin =< 1.5 times ULN

          -  Creatinine =< 1.5 times ULN

          -  Creatinine clearance > 60 mL/min

          -  No uncontrolled congestive heart failure

          -  No unstable angina pectoris

          -  No cardiac arrhythmia

          -  No pulmonary disease requiring oxygen

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No glucose-6-phosphate dehydrogenase (G6PD) deficiency (for patients of African,
             Asian, or Mediterranean origin or ancestry)

          -  No active or ongoing infection

          -  No hypersensitivity or severe allergic reaction to 3-AP (Triapine®) or related
             compounds

          -  No concurrent uncontrolled illness

          -  No psychiatric illness or social situation that would preclude study compliance

          -  No other concurrent antineoplastic therapy

          -  No concurrent combination antiretroviral therapy for HIV-positive patients

          -  No other concurrent investigational therapy for the malignancy
Clinical trial NCT00634205 (phase 2, status: completed)
Conditions: malignant mesothelioma
ICD codes: C45.9, C45.0, C45.1, C45.2, C45.7
Drugs: valproate plus doxorubicin
SMILES: CCCC(CCC)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histological diagnosis of malignant mesothelioma

          -  Unresectable or inoperable malignant mesothelioma failing after at least one prior
             chemotherapy regimen including platinum derivatives (cisplatin or carboplatin)

          -  At least one evaluable or measurable CT-lesion

          -  Availability for participating in the detailed follow-up of the protocol

          -  Signed informed consent

        Exclusion Criteria:

          -  Patients who are candidates for surgery with curative intent

          -  Patient who were previously treated with anthracyclin derivatives

          -  Performance status < 60 on the Karnofsky scale

          -  A history of prior malignant tumour, except non-melanoma skin cancer or in situ
             carcinoma of the cervix and cured malignant tumour (more than 5-year disease free
             interval)

          -  A history of prior HIV infection

          -  Polynuclear cells < 2,000/mm³

          -  Platelet cells < 100,000/mm³

          -  Abnormal coagulation tests (aPTT, PTT, prothrombin time) and/or decreased fibrinogen

          -  Serum bilirubin >1.5 mg/100 ml

          -  Transaminases more than twice the normal range

          -  Serum creatinine > 1.5 mg/100 ml

          -  Recent myocardial infarction (less than 3 months prior to date of diagnosis)

          -  Congestive cardiac failure (ejectional fraction of the left ventricle < 50%) or
             uncontrolled cardiac arrhythmia

          -  Uncontrolled infectious disease

          -  Active epilepsy needing a specific treatment

          -  Concomitant treatment with IMAO, carbamazepine, mefloquine, phenobarbital, primidone,
             phenytoïn, lamotrigine, zidovudine

          -  Pregnancy or refusal to use active contraception

          -  A known allergy to valproate acid and/or doxorubicin

          -  Serious medical or psychological factors which may prevent adherence to the treatment
             schedule